WO2018076049A1 - Protéine immunogène et méthode d'utilisation - Google Patents

Protéine immunogène et méthode d'utilisation Download PDF

Info

Publication number
WO2018076049A1
WO2018076049A1 PCT/AU2017/051164 AU2017051164W WO2018076049A1 WO 2018076049 A1 WO2018076049 A1 WO 2018076049A1 AU 2017051164 W AU2017051164 W AU 2017051164W WO 2018076049 A1 WO2018076049 A1 WO 2018076049A1
Authority
WO
WIPO (PCT)
Prior art keywords
coli
hvh
antibody
isolated protein
protein
Prior art date
Application number
PCT/AU2017/051164
Other languages
English (en)
Inventor
Mark SCHEMBRI
Danilo MORIEL
Original Assignee
The University Of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904314A external-priority patent/AU2016904314A0/en
Application filed by The University Of Queensland filed Critical The University Of Queensland
Publication of WO2018076049A1 publication Critical patent/WO2018076049A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Definitions

  • one form of the invention is broadly directed to an isolated protein comprising the amino acid sequence of SEQ ID NO: l; one or more immunogenic fragments variants and/or derivatives thereof; an isolated nucleic acid encoding said isolated protein, immunogenic fragment, variant and/or derivative; and/or an antibody or antibody fragment that binds said isolated protein, immunogenic fragment, variant and/or derivative, preferably for use in eliciting an immune response in an animal.
  • the invention provides a method of immunizing an animal including the step of administering to the animal: an isolated protein comprising the amino acid sequence of SEQ ID NO: l; one or more immunogenic fragments, variants and/or derivatives thereof; an isolated nucleic acid encoding said isolated protein, immunogenic fragment, variant and/or derivative; and/or an antibody or antibody fragment that binds said isolated protein, immunogenic fragment, variant and/or derivative; to thereby induce immunity to E. coli in the animal.
  • the isolated protein of SEQ ID NO:l, or one or more immunogenic fragments variants and/or derivatives thereof, or the isolated nucleic acid may be administered in combination with one or more additional immunogens that may be specific to certain strains/pathotypes of E coli, or are conserved across a number of different E coli strains/pathotypes.
  • additional immunogens include iron-receptor proteins, fimbrial proteins, flagella, capsular antigens and O antigens.
  • the isolated protein or immunogenic fragment has one, two or no more than three amino acid residues in addition to the recited amino acid sequence.
  • the additional amino acid residues may occur at the N- and/or C-termini of the recited amino acid sequence, although without limitation thereto.
  • the present invention is at least partly predicated on work defining core and accessory E. coli genes that identified YncE as a highly conserved vaccine antigen that is protective against acute E. coli bacteremia.
  • the invention therefore provides methods of immunizing against, preventing and/or treating E. coli infections in animals by administering YncE protein to the animal. This also extends to administering immunogenic YncE fragments, variants, encoding nucleic acids and/or antibodies that bind YncE protein.
  • a particular feature of the invention is that because YncE is "universally" expressed by a plurality of different E. coli strains, serotypes and pathotypes, immunity to YncE may provide immunity to a plurality of different E. coli strains, serotypes and pathotypes.
  • the antibody or antibody fragment may be labelled.
  • the antibody or antibody fragment may be labeled with biotin, an enzyme, fluorophore, radionuclide or other label.
  • the antibody or antibody fragment is unlabeled and a secondary antibody comprises a label.
  • the enzyme may be horseradish peroxidase (HRP), alkaline phosphatase (AP), ⁇ -galactosidase or glucose oxidase, although without limitation thereto.
  • elicits an immune response indicates the ability or potential of a protein, fragment or variant, antibody or encoding nucleic to elicit or generate an immune response to one or a plurality of strains of E. coli, or molecular components thereof, upon administration of to an animal.
  • the immune response may be either B -lymphocyte or T-lymphocyte mediated, or a combination thereof.
  • the immune response includes a B-lymphocyte response, although is not limited thereto, preferably including an antibody response, such as an IgG response.
  • the composition may be a "vaccine" for eliciting a protective immune response to E. coli.
  • the carrier diluent or excipient may include carriers, diluents and/or excipients that have immunological activity, or facilitate immunological activity.
  • these may include: thyroglobulin; albumins such as human serum albumin; toxins, toxoids or any mutant crossreactive material (CRM) of the toxin from tetanus, diphtheria, pertussis, Pseudomonas, E.
  • Controlled release of the therapeutic agent may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose.
  • the controlled release may be effected by using other polymer matrices, liposomes and/or microspheres.
  • An embodiment of an isolated nucleic acid encoding an isolated protein having the amino acid sequence of SEQ ID NO: l comprises the nucleotide sequence of SEQ ID NO:2.
  • operably linked is meant that said additional nucleotide sequence(s) is/are positioned relative to the nucleic acid of the invention preferably to initiate, regulate or otherwise control transcription.
  • said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences.
  • the expression construct may also include an additional nucleotide sequence encoding a fusion partner (typically provided by the expression vector) so that the recombinant protein is expressed as a fusion protein, as hereinbefore described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode de déclenchement d'une réponse immunitaire chez un animal, comprenant l'administration d'une protéine isolée comprenant la séquence d'acides aminés de SEQ ID NO : 1 ; un ou plusieurs fragments immunogènes, variants et/ou dérivés de cette dernière ; un acide nucléique isolé codant pour ladite protéine isolée, le fragment immunogène, le variant et/ou le dérivé ; et/ou un anticorps ou fragment d'anticorps qui se lie à ladite protéine isolée, au fragment immunogène, au variant et/ou au dérivé. Ceci peut immuniser l'animal contre une infection à E. coli et/ou traiter une infection à E. coli existante.
PCT/AU2017/051164 2016-10-24 2017-10-24 Protéine immunogène et méthode d'utilisation WO2018076049A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016904314A AU2016904314A0 (en) 2016-10-24 Immunogenic protein and method of use
AU2016904314 2016-10-24

Publications (1)

Publication Number Publication Date
WO2018076049A1 true WO2018076049A1 (fr) 2018-05-03

Family

ID=62022972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2017/051164 WO2018076049A1 (fr) 2016-10-24 2017-10-24 Protéine immunogène et méthode d'utilisation

Country Status (1)

Country Link
WO (1) WO2018076049A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108588248A (zh) * 2018-05-07 2018-09-28 东北农业大学 用于检测产肠毒素大肠杆菌5种菌毛基因的多重pcr引物组、试剂盒及检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2004018638A2 (fr) * 2002-08-21 2004-03-04 Regents Of The University Of Minnesota Proteines impliquees dans le transport et le metabolisme du fer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2004018638A2 (fr) * 2002-08-21 2004-03-04 Regents Of The University Of Minnesota Proteines impliquees dans le transport et le metabolisme du fer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BABA-DIKWA, A ET AL.: "Overproduction, purification and preliminary X-ray diffraction analysis of YncE, an iron-regulated Sec-dependent periplasmic protein from Escherichia coli", ACTA CRYSTALLOGR SECT F STRUCT BIOL CRYST COMMUN., 1 October 2008 (2008-10-01), pages 966 - 969, XP055479571, Retrieved from the Internet <URL:doi:10.1107/S1744309108029515> *
DATABASE GenBank 16 December 2015 (2015-12-16), Database accession no. ALt45170 *
DATABASE GenBank 31 August 2015 (2015-08-31), Database accession no. ALB31585 *
WURPEL, D J ET AL.: "Comparative proteomics of uropathogenic Escherichia coli during growth in human urine identify UCA-like (UCL) fimbriae as an adherence factor involved in biofilm formation and binding to uroepithelial cells", JOURNAL OF PROTEOMICS, vol. 131, 3 November 2015 (2015-11-03), pages 177 - 189, XP029313481, Retrieved from the Internet <URL:doi:10.1016/j.jprot.2015.11.001> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108588248A (zh) * 2018-05-07 2018-09-28 东北农业大学 用于检测产肠毒素大肠杆菌5种菌毛基因的多重pcr引物组、试剂盒及检测方法
CN108588248B (zh) * 2018-05-07 2021-08-27 东北农业大学 用于检测产肠毒素大肠杆菌5种菌毛基因的多重pcr引物组、试剂盒及检测方法

Similar Documents

Publication Publication Date Title
Abdelhamed et al. Evaluation of three recombinant outer membrane proteins, OmpA1, Tdr, and TbpA, as potential vaccine antigens against virulent Aeromonas hydrophila infection in channel catfish (Ictalurus punctatus)
Bruxelle et al. Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models
Yang et al. OmpN, outer membrane proteins of Edwardsiella ictaluri are potential vaccine candidates for channel catfish (Ictalurus punctatus)
Zhang et al. GapA, a potential vaccine candidate antigen against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)
CA2792956C (fr) Composants de vaccin bacterien provenant du staphylocoque dore et leurs utilisations
US20230256071A1 (en) Virulent aeromonas vaccines and methods
Jagusztyn-Krynicka et al. Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis
US9597386B2 (en) Outer membrane proteins of Histophilus somni and methods thereof
Sharma et al. Immune response characterization and vaccine potential of a recombinant chimera comprising B-cell epitope of Aeromonas hydrophila outer membrane protein C and LTB
WO2006113907A2 (fr) Proteines d&#39;escherichia coli o157:h7 et utilisations de ces proteines
WO2018076049A1 (fr) Protéine immunogène et méthode d&#39;utilisation
Asper et al. Cross reactivity of enterohemorrhagic Escherichia coli O157: H7-specific sera with non-O157 serotypes
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
US8647640B2 (en) Vaccine compositions and methods of use to protect against infectious disease
Dwivedi et al. Lipoproteins from Clostridium perfringens and their protective efficacy in mouse model
US20100068214A1 (en) Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus
Zaheer et al. Expeditious screening of candidate proteins for microbial vaccines
US9579370B2 (en) Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination
US9562080B2 (en) Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine
US10226520B2 (en) Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination
Ipe et al. A Novel Protective Vaccine Antigen from the Core Escherichia coli Genome
Bravo Characterization and detection of antibodies to candidate Rhodococcus equi vaccine antigens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17865228

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17865228

Country of ref document: EP

Kind code of ref document: A1